Jason B. Muhitch, PhD

home / authors / jason-muhitch-phd

Articles

An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.

Kidney Cancer Research Program May Play Pivotal Role in Advancing Care

Elizabeth P. Henske, MD;Jason B. Muhitch, PhD
December 20th 2024

An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.

Kidney cancer advocacy efforts have spread the urgency and importance of funding research in the field to members of Congress.

Connecting With Congress to Advance Kidney Cancer Research

Elizabeth P. Henske, MD;Jason B. Muhitch, PhD
December 19th 2024

Kidney cancer advocacy efforts have spread the urgency and importance of funding research in the field to members of Congress.

Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.

Collaboration and Research Funding Advancements in Kidney Cancer Advocacy

Elizabeth P. Henske, MD;Jason B. Muhitch, PhD
December 18th 2024

Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.

Two oncologists discuss the impact of advocacy in kidney cancer research, highlighting collaboration between researchers, advocates, and physicians.

Highlighting Advocacy Impacts on Funding for Kidney Cancer Research

Elizabeth P. Henske, MD;Jason B. Muhitch, PhD
December 16th 2024

Two oncologists discuss the impact of advocacy in kidney cancer research, highlighting collaboration between researchers, advocates, and physicians.

Latest Updated Articles

Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
45-Year-Old Female With Gross Hematuria Post Partial Nephrectomy
Published: March 1st 2018 | Updated: January 18th 2025
45-Year-Old Female With Gross Hematuria Post Partial Nephrectomy
4 experts are featured in this series.
Published: January 13th 2025 | Updated: January 18th 2025
ASH 2024 Updates —AURIGA: Daratumumab Plus Lenalidomide in Maintenance Post Transplant